Citations

Clear

904 citation(s) found for "Gordon, S".

Gaps in Guideline Adherence for Primary Sclerosing Cholangitis in North America—A 5‐Year Analysis
Martins, Adrielly , Reddy, A. Nagarjuna, Dean, Richard, Gordon, Stuart C. , Pratt, Daniel, Li, Michael, Forman, Lisa , Lammert, Craig , Yiman, Kidist, Gallegos‐Orozco, Juan F. , Carey, Elizabeth J. , Lytvyak, Ellina , Goldberg, David S. , Naugler, Scott, Yu, Lei, Assis, David N. , Bowlus, Christopher L., Bowlus, Christopher L. , Bonder, Alan , Schlansky, Barry L , Montano-Loza, Aldo J , Lytvyak, Ellina , Goldberg, David , Assis, David N , Levy, Cynthia , Bowlus, Christopher L , Reddy, Anish , Dean, Richard , Li, Michael, Montaño‐Loza, Aldo J. , Levy, Cynthia

Mayo Clinic

Liver International | April 11, 2026 | Volume: 46 | Issue: 5 | Pages: No page available

10.1111/liv.70645 | PMID 41964270 Get It

ABSTRACT Background and Aims Primary sclerosing cholangitis (PSC) is a progressive cholestatic liver disease with a high risk of malignancy and limited therapeutic options. Both the American Association for the Study of Liver Diseases (AASLD) and the European Association for the Study of the Liver (EASL) recommend structured baseline evaluation, fibrosis staging and longitudinal surveillance. However, real‐world adherence to these practices in North America remains unclear. Methods We conducted a retrospective cohort study of 1300 patients with PSC enrolled in the Consortium for Autoimmune Liver Diseases (CALiD) registry between 2018 and 2024 across 19 centres in North America. Guideline adherence was assessed for diagnostic measures at baseline (colonoscopy to establish IBD status and noninvasive fibrosis staging) and longitudinal surveillance (colonoscopy in PSC‐IBD, abdominal imaging for hepatobiliary cancer surveillance and CA 19‐9 testing). Prescribing patterns for ursodeoxycholic acid (UDCA) were also characterised. Multivariable logistic regression was used to evaluate demographic, clinical and socioeconomic predictors of adherence. Results At diagnosis, 78.8% of eligible patients with available data underwent colonoscopy to establish IBD status, and 45% underwent noninvasive fibrosis staging. During follow‐up, only 30%–35% of patients with PSC‐IBD underwent colonoscopy annually, while abdominal imaging for hepatobiliary cancer surveillance declined from 74% at Year 1 to 51% by Year 4. CA 19‐9 testing was documented in 47% over 5‐year period. UDCA was prescribed in 51% at baseline, with median dose of 12.5 mg/kg/day. Socioeconomic factors, including lower education and household income, were associated with reduced adherence, while cirrhosis strongly predicted completion of surveillance imaging. Conclusions Adherence to guideline‐based care in PSC remains suboptimal in North America Suboptimal adherence was observed for strongly recommended practices with longstanding guideline support (colonoscopy to establish IBD status; annual CRC surveillance in PSC‐IBD) as well as practices where guideline consensus has evolved more recently or where societies differ (baseline fibrosis assessment; hepatobiliary cancer imaging). Efforts to standardise care and address socioeconomic barriers are urgently needed to improve outcomes.
Effect of Cognitive Reserve on Age at Symptom Onset and Cognitive Decline in Individuals With Dominantly Inherited Alzheimer Disease
Llibre‐Guerra, Jorge J. , Lu, Ruijin , Clarens, Ma. Florencia, Liu, Ian, Renton, Alan, Ryan, Natalie S. , Goate, Alison , Aguillón, David , Benzinger, Tammie L.S. , Chhatwal, Jasmeer P. , Chrem-Méndez, Patricio , Vigo, Gabriela , Farlow, Martin R., Huey, Edward D. , Perrin, Richard J. , Wang, Guoqiao, Li, Yan, Xiong, Chengjie, Daniels, Alisha , Goate, Alison M , Benzinger, Tammie L S , Berman, Sarah , Chhatwal, Jasmeer , Chrem Mendez, Patricio , Vigo, Gabriela , Cruchaga, Carlos , Day, Gregory S , Fox, Nick C , Gordon, Brian A , Hassenstab, Jason , Huey, Edward D , Ibanez, Laura , Ikeuchi, T , Jucker, Mathias , Lee, Jae‐Hong , Levey, Allan I , Xiong, Chengjie , Niimi, Yoshiki , Perrin, Richard , Rosa-Neto, Pedro , Sánchez-Valle, Raquel , Schofield, Peter R , Morris, John C , Karch, Celeste M , Daniels, Alisha , McDade, Eric M , Bateman, Randall J , Llibre-Guerra, Jorge J , Aguillon, David , Clarens, María Florencia , Renton, Alan , Allegri, Ricardo , Berman, Sarah , Day, Gregory S. , Farlow, Martin R. , Fox, Nick C. , Gordon, Brian A. , Hassenstab, Jason , Ikeuchi, Takeshi , Levey, Allan I. , Xiong, Chengjie , Sánchez‐Valle, Raquel , Schofield, Peter R. , Wang, Guoqiao , Li, Yan , Xiong, Chengjie , Morris, John C. , Karch, Celeste M. , McDade, Eric , Bateman, Randall J.

Mayo Clinic

Neurology | April 8, 2026 | Volume: 106 | Issue: 8 | Pages: No page available

10.1212/wnl.0000000000214804 | PMID 41950468 Get It

Abnormalities in core AD biomarkers precede inflammatory and glial markers in CSF in Autosomal Dominant Alzheimer’s Disease
Lin, Wenjing , Beric, Aleksandra , Baker, Bryce, Jerome, Gina, Minton, Matthew, Preminger, Sam Rose, Stauber, Jennifer, Schindler, Suzanne E, Dage, Jeff L., Aguillon, David, Benzinger, Tammie L.S., Chhatwal, Jasmeer, Daniels, Alisha , Day, Gregory, Devenney, Emma , Fox, Nick, Goate, Alison, Gordon, Brian A., Barthélemy, Nicolas R., Hassenstab, Jason, Huey, Edward D. , Jayadev, Suman, Ishiguro, Takanobu , Lee, Jae-Hong, Levey, Allan I., Levin, Johannes, Morris, John C, Perrin, Richard J., Renton, Alan E., Xiong, Chengjie, Ances, Beau M., McDade, Eric, Network, Dominantly Inherited Alzheimer, Dage, Jeffrey L. , Wisch, Julie K , Dage, Jeffrey L , Allegri, Ricardo , Aguillon, David , Benzinger, Tammie L S , Chhatwal, Jasmeer , Daniels, Alisha , Day, Gregory S , Goate, Alison M , Gordon, Brian A , Huey, Edward D , Ikeuchi, T , Jucker, Mathias , Ishiguro, Takanobu , Roh, Jee Hoon , Bateman, Randall J , Cruchaga, Carlos , Karch, Celeste M , Supnet-Bell, Charlene , Llibre-Guerra, Jorge J , Ibanez, Laura , Wisch, Julie K. , Baker, Bryce, Schindler, Suzanne E. , Allegri, Ricardo , Benzinger, Tammie L.S. , Chhatwal, Jasmeer P. , Day, Gregory S. , Fox, Nick C. , Goate, Alison , Gordon, Brian A. , Barthélemy, Nicolas R. , Hassenstab, Jason , Ikeuchi, Takeshi , Jayadev, Suman , Levey, Allan I. , Xiong, Chengjie , Morris, John C. , Perrin, Richard J. , Renton, Alan , Roh, Jee Hoon , Xiong, Chengjie , Bateman, Randall J. , Ances, Beau M. , Karch, Celeste M. , Supnet, Charlene , Llibre‐Guerra, Jorge J. , McDade, Eric , Network, Dominantly Inherited Alzheimer

Mayo Clinic

No container title available | April 1, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.03.31.26349851 | PMID 41959774 Get It

ABSTRACT BACKGROUND Increasing evidence suggests that accurate prediction of Alzheimer’s disease (AD) symptom onset requires more than amyloid- and tau-centric biomarkers such as cerebrospinal fluid (CSF) Aβ42/40, total tau and p-tau181 and plasma p-tau217. Autosomal dominant AD (ADAD), caused by pathogenic PSEN1, PSEN2 and APP mutations with predictable age at symptom onset, presents a unique opportunity to characterize the chronological changes in proteins beyond amyloid and tau and clarify them as early biomarkers of disease onset or as biomarkers related to disease staging and progression monitoring. METHODS We measured 972 CSF samples corresponding to 484 participants of the Dominantly Inherited Alzheimer Disease Network (DIAN) using the NULISASeq 120 CNS Disease Panel. We first benchmarked the technology against gold-standard measurements followed by the identification of proteins that were differentially abundant in relation to mutation status and symptomatology. Next, we determined the chronological emergence of protein changes in relation to the estimated years to onset (EYO). Finally, we assessed whether specific protein measures improved the prediction of EYO in the ADAD. FINDINGS NULISA measurements were comparable to those previously published. We demonstrated that known early alterations in CSF amyloid and tau were followed by inflammatory and neurodegenerative responses suggesting that clinical manifestation of AD happens before the inflammatory processes is fully developed. Finally, we found a multi-protein composite approach for predicting EYO that outperformed single biomarker values. INTERPRETATION Our results suggest that the main CSF proteomic landscape changes in ADAD are due to the presence of a pathogenic mutation and occur prior to symptom onset. Improved performance of multi-protein composite to predict EYO compared to single biomarker values highlights the added value of multiplex proteomic signatures for biomarker panel development. FUNDING National Institute on Aging, Alzheimer’s Association, German Center for Neurodegenerative Diseases, Raul Carrea Institute for Neurological Research, Japan Agency for Medical Research and Development, Ministry of Health & Welfare and Ministry of Science and ICT, Republic of Korea, Spanish Institute of Health Carlos III.
Magnetic resonance–guided focused ultrasound for the management of tremor: update on the position statement of the American Society for Stereotactic and Functional Neurosurgery
Elias, W. Jeffrey, Baltuch, Gordon H., Machado, Andre G., Sweet, Jennifer A. , Englot, Dario J., Lipsman, Nir , Cosgrove, G. Rees, Ali, Rushna , Pilitsis, Julie G., Danish, Shabbar F. , Ali, Rushna , Hamani, Clement , Elias, W. Jeffrey , Gross, Robert E. , Rosenow, Joshua M. , Schwalb, Jason M. , Air, Ellen L. , Machado, André G. , Willie, Jon T , Rolston, John D. , Englot, Dario J. , Zemmar, Ajmal , Neimat, Joseph S. , Cosgrove, Garth Rees , Asaad, Wael F. , Pilitsis, Julie G.

Mayo Clinic

Journal of Neurosurgery | March 28, 2026 | Volume: No volume available | Issue: No issue available | Pages: 1-9

10.3171/2025.11.jns251828 | PMID 41894813 Get It

OBJECTIVE Magnetic resonance–guided focused ultrasound (MRgFUS) thalamotomy has become a popular tool in the neurosurgical armamentarium for managing tremor in patients with essential tremor (ET) and Parkinson’s disease (PD). METHODS Given the recent exponential growth in the use of this technology, the American Society for Stereotactic and Functional Neurosurgery, which acts as the joint section representing the field of stereotactic and functional neurosurgery on behalf of the Congress of Neurological Surgeons and the American Association of Neurological Surgeons, provides an update on treatment indications and the efficacy and safety of MRgFUS for the treatment of tremor. RESULTS In ET, the efficacy of MRgFUS thalamotomy is supported by several open-label and 1 prospective, double-blind, sham-controlled randomized clinical trial (RCT) that showed a 47% improvement in hand tremor in the short term. Follow-up studies demonstrated that the benefits of MRgFUS for ET are sustained in the long term. Studies investigating the effects of bilateral staged MRgFUS thalamotomy in patients with ET have shown that tremor improvement on the second side was as significant as that observed after the first procedure. The efficacy of MRgFUS thalamotomy for PD tremor is supported by a systematic meta-analysis that consisted predominantly of smaller, nonrandomized studies; 1 RCT; and 1 prospective cohort study. Despite a significant short-term improvement in PD tremor, the long-term effects of this therapy remain unknown. Common early adverse effects of MRgFUS thalamotomy include gait disturbance and paresthesias. These, however, tend to subside over time. Other reported side effects are dysarthria, ataxia, taste disturbance, motor deficits, and speech difficulty. CONCLUSIONS MRgFUS thalamotomy is a safe, effective, and durable intervention for refractory ET in appropriately selected patients. The procedure appears to be safe and effective for PD tremor, although the long-term durability of the technique remains a concern. Early experience with bilateral staged lesions for ET suggests the procedure to be safe and effective.
Contemporary Adjuvant Chemotherapy for Intraductal Papillary Mucinous Neoplasms
Haugk, Beate , White, Steven, Marchegiani, Giovanni, Holmberg, Marcus, Zerbi, Alessandro, Lu, Zipeng , Inoue, Y., Choi, Munseok , Kang, Chang Moo, Visser, B., Corpelijn, Lieke, Andersson, Bodil, Bereza-Carlson, Paulina, Björnsson, Bergthor, Wennerblom, Johanna, Goh, Brian K. P., Hartman, V., Ahmad, Syed, Patel, Sameer, Berrevoet, Frederik, Mortensen, Kim Erlend, Roberts, K., Lynch, Calum, Gupta, Amit, Kleeff, Joerg, Addeo, Pietro, Friess, Helmut, Koea, Jonathan, Gomez, Dhanny , Gordon-Weeks, Alex, Doria, Cataldo, Tzimas, Georgios, Franklin, O., Månsson, C., Cabús, Santiago Sánchez, Bhogal, Ricky H. , Pathak, Samir, Honselmann, Kim Christin, Balakrishnan, Anita, Mann, Kulbir , Gill, Anthony J., Mittal, A, Samra, Jas, Athwal, Tejinderjit, Loveday, Benjamin, Bhardwaj, Neil, Menon, Krishna, Thapa, Prabin, Matsumoto, Ippei, Jamieson, Nigel, Rebours, Vinciane, Descourvières, Clémence, Davidson, BR, Soreide, Kjetil, Pandanaboyana, Sanjay, Collaborative, Adeno-IPMN2, Kumar, Ajit, González, Carol Natalia Clavijo, Lam, Shi, L’Official-German, Ivan, Bergner, Tina, Rosso, Edoardo , Giulianotti, Pier Cristoforo , Morreau, Mathew , Dili, Alexandra, Sotiropoulou, Maria , Kuzman, Matta , Büyükkasap, Ahmet Çağrı, Uludağ, Gökhan, McGuigan, Mari-Claire , Chouari, Tarak , Dogul, Ahmet, Doğu, Doğukan , Rebelo, Artur, Holewik, Franziska Bernadette, Plesa-Furda, Roxana, Revoredo, Fernando, Galanis, Ilias , Maharjan, Dhiresh, Ghorbani, Poya , Lind, Max, Ami, Katsuya , Vijayashanker, Aarathi , Alsaoudi, Tareq , Lundgren, Linda , Ellisa, Katrina, Hong, Paul , Gupta, Archit, MartinXu, Congde, Konstantoudakis, Georgios, Christophides, Thalis, Spurring, Eleanor Margaret, Iwao, Yasuhito, Pirklc, Martin, Vaitha, Ruhi , Tiwari, Navneet, Sheel, Andrea, Kotecha, Krishna , Stavrou, Gregor A., Patel, Rikhilroy, Misca, Mihaela , Hammond, John, Roalso, Marcus Thomas Thor, Soomro, Faiza H, Halimi, Asif , Kendall, Timothy, Patel, Visad, Stankic, Dunja, Dries, Pieter , Hein, Charlotte, Betram, Julia, Jacob, Rosetta, Wilson, Gregory, Redas, Souheil, Poškus, Augustas, Mosert, Paula Lucia, Šilinskaitė, Ugnė , Hirose, Yuki, Liu, Xue, Standaert, Lars, Kay, Tegan J, Nishida, Kenji, Peddakota, Vivek , Gupta, Amit , Kang, Chang Moo , Ven Fong, Zhi, Kang, Chang Moo , Lucocq, James E. , Marchegiani, Giovanni , Zerbi, Alessandro , Pagnanelli, Michele , Visser, B. , Andersson, Bodil , Bereza‐Carlson, Paulina , Björnsson, Bergþór , Wennerblom, Johanna Hansson , Labori, Knut Jørgen , Goh, Brian K P , Hartman, Vera , Berrevoet, Frederik Christiaan , Ausania, Fabio , Bertrand, Claude , Kleeff, Joerg, Addeo, Pietro , Bellotti, Ruben , Fong, Zhi Ven , Friess, Helmut , Koea, Jonathan , Gordon-Weeks, Alex Nicolas , Doria, Cataldo , Franklin, Oskar , Pathak, Samir , Honselmann, Kim C. , Balakrishnan, Anita , Harrison, Ewen M. , Gill, A J, Mittal, Anubhav, Samra, Jas , Athwal, Tejinderjit , Loveday, Benjamin P. T. , Teh, Catherine , Bhardwaj, Neil , Menon, Krishna, Matsumoto, Ippei , Jamieson, Nigel , Rebours, Vinciane , Søreide, Kjetil , Martlı, Hüseyin Fahri , Roeyen, Geert , Antonakis, Pantelis T. , Bramis, Konstantinos , Hall, Lewis A , Valle, Valentina , Connor, Saxon J. , Kapiris, Stylianos A. , Kerem, Mustafa , Rebelo, Artur , Plesa-Furda, R., Filho, Omero Pereira da Costa , Galanis, Ilias, Konstantoudakis, Georgios, Christophides, Thalis, McGuinness, Matthew James , Yaqub, Sheraz , Pellegrini, Riccardo , Perri, Giampaolo , Sheel, Andrea , Sheen, Amy , Evans, Daisy, Ghamarnejad, Omid , Karavias, Dimitrios D. , Roalsø, Marcus T. T. , Stankic, Dunja , Grubor, Nikica , Gulla, Aistė , Furukawa, Takaaki , Hirose, Yuki , Yin, Lingdi , Inoue, Yosuke

Mayo Clinic

JAMA Network Open | March 27, 2026 | Volume: 9 | Issue: 3 | Pages: e263688

10.1001/jamanetworkopen.2026.3688 | PMID 41893840 Get It

Importance Adjuvant chemotherapy regimens may be administered after pancreatic resection for adenocarcinoma arising from intraductal papillary mucinous neoplasms (A-IPMNs), although the evidence supporting their use is limited. Objective To evaluate the survival benefit associated with contemporary adjuvant chemotherapy regimens after resection in A-IPMNs between 2017 and 2023. Design, Setting, and Participants This retrospective cohort study was an international, multicenter study with 69 participating centers across Europe, North America, South America, and the Asia-Pacific region. Patients undergoing resection for A-IPMNs were included. Data were analyzed from May to August 2025. Intervention Contemporary adjuvant chemotherapy regimens, such as gemcitabine-capecitabine (GemCap); 5-fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFIRINOX), modified FOLFIRINOX (mFOLFIRINOX), and S-1. Main Outcome and Measure Overall survival (months). Results Among 1321 patients (median [IQR] age 70 [63 to 76] years; 713 males [54.0%] and 608 females [46.0%]), 781 patients (59.1%) received adjuvant chemotherapy, while in 181 patients (13.7%) it was omitted due to poor patient fitness. Of patients who received adjuvant chemotherapy, 568 patients (72.6%) received contemporary regimens, including GemCap (232 patients [29.7%]), FOLFIRINOX (176 patients [22.5%]), mFOLFIRINOX (71 patients [9.1%]), and S-1 (70 patients [9.0%]). The median (IQR) follow-up for the cohort was 64.2 (40.4 to 85.0) months, and the median overall survival was 73.8 months (95% CI, 66.4 to 81.9 months). After 90-day landmark analysis and exclusion of patients ineligible for chemotherapy, adjuvant chemotherapy vs no adjuvant chemotherapy (propensity score–matched populations, 243:243 patients) was not associated with improved overall survival (median, 82.3 months; 95% CI, 78.2 months to not applicable [NA] vs not reached; 95% CI, 75.3 months to NA; P = .58). Contemporary regimens vs no adjuvant chemotherapy (propensity score–matched populations, 309:309 patients) was not associated with longer survival, and a mean survival benefit greater than 4.2 months over 5 years was excluded (difference in restricted mean survival, 1.26 months; 95%, −1.72 to 4.24 months). Treatment outcomes did not vary by chemotherapy regimen or disease characteristic (eg, N stage or carbohydrate antigen 19-9 level). Conclusions and Relevance In this study, contemporary adjuvant chemotherapy was not associated with improved overall survival in A-IPMNs, and a randomized clinical trial is indicated.
Utility of the Early Sjögren Antibody Panel as a Diagnostic Marker for Sensory Neuropathy
Zeidman, Lawrence A. , Fawaz, Cherine N., Phillips, Stephanie Gordon, Latack, Katie, Fawaz, Cherine , Phillips, Stephanie

Mayo Clinic

Muscle & Nerve | March 17, 2026 | Volume: 73 | Issue: 6 | Pages: 1146-1150

10.1002/mus.70204 | PMID 41839642 Get It

ABSTRACT Introduction/Aims:. Primary Sjögren syndrome (SS) is a chronic autoimmune disease characterized frequently by sensory neuropathy (SN). Carbonic Anhydrase‐6 (CA‐6), Parotid Secretory Protein (PSP), and Salivary Protein‐1 (SP‐1) antibodies (Early Sjögren antibodies [ESA]) are found in 45% of SS patients who lack traditional antibodies (Ro/La). But there is a lack of information regarding whether ESA are associated with SN, and if there are any identifying characteristics associated with ESA in SN. Our goal was to close this knowledge gap. Methods All SN patients tested for ESA from May 2023–October 2024 were retrospectively analyzed for clinical features such as sicca symptoms, onset acuity, small fiber neuropathy (SFN)‐questionnaire scores, and pathological features such as length‐dependence/vasculitis on skin biopsies, as well as lip biopsy confirmation of SS. Seropositive/seronegative groups were separated for statistical analysis. Results Thirty‐three adult patients (73% female) with cryptogenic SN had ESA testing. Eighteen (55%) had abnormal ESA. Twelve (100%) seropositive patients had significant sicca symptoms versus four seronegative patients (29%) ( p = 0.0002). There were no significant associations between ESA seropositivity and SFN‐questionnaires, pathological nonlength dependence (NLD)/vasculitis, or onset acuity. Discussion ESA may be seen in more than half of cryptogenic SN patients, but whether these patients have confirmed SS is unclear. Seropositive patients more frequently have significant sicca symptoms than seronegative patients, but no other significant identifying characteristics were seen. Further work on a larger population should be done to confirm these findings, but this study suggests the utility of checking ESA in cryptogenic SN patients with significant sicca symptoms.
Defining Quality Metrics for Telemedicine in Surgery: A Critical Examination
Shao, Connie , Brooke, Benjamin S, Wisbach, Gordon , Sawyer, Mark D. , Redan, Jay, Adelson, P David, Singh, Niten, Woo, Russell, Hashmi, Zain G. , Brooke, Benjamin S. , Huang, Eunice Y. , Adelson, P. David , Sewell, Marisa , Woo, Russell

Mayo Clinic

Journal of the American College of Surgeons | March 12, 2026 | Volume: 243 | Issue: 2 | Pages: 443-449

10.1097/xcs.0000000000001922 | PMID 41817107 Get It

The rapid adoption of telemedicine has transformed healthcare delivery in the US, enhancing access and communication for surgical patients across wide geographic areas. However, a critical challenge persists: the need to define and standardize quality metrics specifically for telemedicine in surgery. Existing studies suggest that telemedicine can yield equivalent or improved outcomes compared with in-person visits. Nevertheless, literature remains limited in evaluating patient satisfaction, cost-effectiveness, and diagnostic accuracy. Through expert consensus within the American College of Surgeons Board of Governors Telehealth Pillar, we propose a structured framework for defining and implementing quality metrics for surgical telemedicine. This is based on the Donabedian model, addressing structure, process, and outcome, while also considering the distinct phases of surgical care: preoperative, intraoperative, and postoperative. This framework identifies unique domains of telemedicine in surgical care, emphasizing hospital and organizational structure, patient and provider readiness, and policy alignment. A comparative analysis with existing AHRQ and WHO frameworks highlights gaps in surgical applicability. Finally, we propose an implementation roadmap prioritizing immediate, feasible metrics while identifying areas for future validation. Collaboration among researchers, clinicians, and policymakers will be essential to establish these metrics and ensure that telemedicine delivers on its potential to improve surgical care delivery while addressing disparities in access and outcomes.
Intraductal digestive enzyme accumulation drives lethal hemorrhagic necrotizing pancreatitis and enables therapeutic intervention
Ji, Baoan , Wang, J., Wang, Lingxiang , Wang, Bin, Wan, Jianhua, He, Gordon, Jahan-mihan, Yasmin, Li, Audrey, Wang, Y., Feng, Donfeng, Clark, Justin J., Faheem, Muhammad, Wang, Oliver H., Zhu, Zhu, Tu, Guangping, Yu, Xiao, Waldron, Richard T. , Lugea, Aurelia, Pandol, Stephen, Edenfield, Brandy , zhang, lizhi, Bi, Yan, Wang, Jiale , Wang, Jiale , Wang, Yuxi, Hu, Jie , Pandol, Stephen J , Wang, Ying , Waldron, Richard T , Liu, Yang , Wan, Jianhua , Jahan‐mihan, Yasmin , Hu, Jie , Clark, Justin, Pandol, Stephen J. , Wang, Ying

Mayo Clinic

No container title available | March 6, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-7861443/v1 | PMID 41836514 Get It

Abstract Background: Hemorrhagic necrotizing pancreatitis (HNP) is a highly lethal form of pancreatitis that lacks mechanism-based therapy. Intra-acinar enzyme activation is fundamental to pancreatitis initiation, yet it does not explain why only a subset of episodes progress to catastrophic hemorrhagic necrosis. Objective: To identify determinants of progression to lethal HNP and test a mechanism-based preventive intervention. Design: Using humanized trypsinogen mouse models and secretagogue regimens, we compared high-dose cerulein with low/moderate-dose cerulein and bombesin. We quantified pancreatic protease activity, performed blinded histopathologic scoring, assessed hemorrhage/vascular disruption, and evaluated enzyme localization and ductal injury by PRSS1 immunostaining. De-identified human pancreatic histology from HNP were examined. We tested a repurposed strategy using clinically approved agents for other indications: secretin to stimulate ductal fluid secretion and isosorbide mononitrate (ISMN) to promote ductal outflow via sphincter of Oddi relaxation. Results: High-dose cerulein induced robust intrapancreatic protease activation but predominantly caused edematous pancreatitis. Paradoxically, bombesin and low/moderate-dose cerulein elicited lower total pancreatic protease activity yet produced severe, frequently lethal HNP with vascular disruption and lobular ischemic necrosis. HNP was associated with intraductal enzyme accumulation and ductal injury. Secretin or ISMN alone showed limited protection, whereas combined secretin+ISMN prevented hemorrhagic necrotizing injury. Conclusion: Pancreatitis severity is determined not only by the magnitude of enzyme activation but also by where enzyme activity is exerted, implicating intraductal enzyme accumulation as a mechanistic determinant and therapeutic target in HNP. Coordinated enhancement of ductal secretion and outflow with clinically approved agents prevents HNP in vivo, supporting a translatable prevention strategy.
Demographic factors and rural residence history associated with smoking history
Reed, Tyra, Gordon, Destiny, Dyal, Brenda W. , KL, Powell-Roach, Ezenwa, Miriam O. , Johnson-Mallard, Versie, Odedina, Folakemi T., Yao, Yingwei, Wilkie, Diana J. , Powell-Roach, Keesha , Powell-Roach, Keesha , Krieger, Janice L. , Wilkie, Diana J , Johnson‐Mallard, Versie

Mayo Clinic

Journal of the American Association of Nurse Practitioners | February 24, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/jxx.0000000000001257 | PMID 41733483 Get It

Background: Understanding personal and geographic factors associated with smoking is important to design and implement interventions focused on reducing cancer health disparities. Scant research has been published recently regarding factors associated with smoking history associations within rural communities. Purpose: To examine demographic factors and rural residence history for associations with smoking history. Methodology: In a cross-sectional study of cancer-related behaviors, 1,786 adults (mean age 47.9 ± 17.5 years; 53% female, 84% White) completed an online survey in 2020. We examined factors associated with smoking history (having smoked at least 100 cigarettes) using independent t-tests, chi-square tests, and logistic regression. Results: Of the participants, 36% had a rural residence history and 49% had a smoking history. A larger proportion of men than women (61% vs. 37%; p < .001), White than Black participants (50% vs. 39%; p = .001), and rural than nonrural residents (53% vs. 46%; p = .005) had a smoking history. Logistic regression analysis revealed that the young age group (18–30) was less likely ( p = .002), whereas the middle age group (31–50) was more likely ( p < .001) to have a smoking history than those older than 50 years. Rural residence was associated with a smoking history among women ( p < .001), but not among men ( p = .70) in this sample. Conclusions: Tobacco control efforts are needed to focus on middle-aged men in general and women with rural residence history. Implications: Nurse practitioners are uniquely positioned to directly contribute to future research with self-identified rural populations that could help inform future public health policy.